# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2020

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2020-11-13
- Accepted by EDGAR: Nov 13, 2020, 16:45 ET
- Period: 2020-09-30
- Accession: 0001477932-20-006527
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000147793220006527/celz_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000147793220006527/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $77.0k | us-gaap:Revenues |
| Revenue | 9 months, 2020-01-01 to 2020-09-30 | $147.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-07-01 to 2020-09-30 | $17.6k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2020-01-01 to 2020-09-30 | $42.6k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-07-01 to 2020-09-30 | $59.4k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-01 to 2020-09-30 | $104.4k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2020-07-01 to 2020-09-30 | $285.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-09-30 | $846.2k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | −$242.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | −$791.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $289.2k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $910.2k | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-07-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | $394.9k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | $2.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-09-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-01 to 2020-09-30 | 1,362,884,982 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-09-30 | 1,073,679,898 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | −$491.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2020-09-30 | $38.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $38.7k | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $425.2k | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $3.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $3.2m | us-gaap:Liabilities |
| Long-term debt | at 2020-09-30 | $1.2m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2020-09-30 | −$2.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,177 characters.

*Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2019, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.*

### Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

### Overview

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on urology, orthopedics and neurology using adult stem cell treatments.

We currently conduct substantially all of our commercial operations through Creative Medical Technologies, Inc. (“CMT”) our wholly-owned subsidiary. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 15 locations in the United States and Europe.

We are currently focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the United States, Europe and South America, and commercializing our StemSpine® treatment for lower back pain. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products that utilize our proprietary intellectual property.

Our principal executive offices are located at 211 E Osborn Road, Phoenix, AZ 85012.

During the first nine-months of 2020, we issued $532,850 in convertible notes with net proceeds of $458,600 to accredited investors.

14

#### Table of Contents

During the nine-month period ending September 30, 2020, we incurred interest expense of $105,338 arising from the third-party notes of $1,197,354.

#### Plan of Operations

We commenced marketing disposable stem cell concentration kits for the CaverStem® erectile dysfunction treatment in the fourth quarter of 2017 and the FemCelz® female sexual dysfunction treatment in March of 2019. The Company also announced the commercialization of the StemSpine procedure for lower back pain in the fourth quarter of 2019. We also continued to make progress towards filing an Innovative New Drug (IND) application for the Amniostem universal donor stem cell to treat stroke and neurodegenerative conditions. For the next 12 months our plan of operations is to continue to expand the market for the CaverStem® and FemCelz® procedures, launch the StemSpine procedure, file an IND application on Amniostem and partner with leading researchers to initiate the Amniostem trial. As of September 30, 2020, we had approximately $39,000 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least August 2020. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable stem cell concentration kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

### Results of Operations – For the Three-month Period Ended September 30, 2020 and 2019

***Gross Revenue.*** We generated $77,000 gross revenue for the three-month period ended September 30, 2020, in comparison with $57,500 for the comparable quarter a year ago. The increase of $19,500 or 34% reflects the return to a growth trajectory as the effects of the COVID-19 pandemic begin to dimmish.

***Cost of Goods Sold***. We generated $17,600 cost of goods sold for the three-month period ended September 30, 2020, in comparison with $8,000 for the comparable quarter a year ago. The increase of $9,600 or 120% is due to the increased revenues and slightly lower gross margins as incentives were offered to new physician providers.

***Gross Profit/(Loss)***. We generated $59,400 in gross profit for the three-month period ended September 30, 2020, in comparison with $49,500 for the comparable quarter a year ago. The increase of $9,900 or 20% is due to the increased revenues and reduced margins referenced above.

***General and Administrative Expenses.*** General and administrative expenses for the three-month period ended September 30, 2020, totaled $301,871 in comparison with 322,922, for the comparable quarter a year ago. The decrease of $21,051 or 7% is primarily due to a decrease of $23,898 in travel expenses.

***Research and Development Expenses.*** There were no research and development expenses for the three-month period ended September 30, 2020, and for the comparable quarter a year ago.

***Other Income / Expense.*** Other income for the three-month period ended September 30, 2020, totaled $637,322 in comparison with other expense of $2,132,702, for the comparable quarter a year ago. The increased income of $2,770,024, or 130% is primarily due to a gain in the fair value of derivative liabilities of $926,532, and a $239,978 reduction in interest expense.

***Net Income/Loss.*** For the reasons stated above, our net income for the three-month period ended September 30, 2020, totaled $394,851 in comparison to a loss of $2,406,124, for the comparable quarter a year ago.

15

#### Table of Contents

### Results of Operations – For the Nine-month period Ended September 30, 2020 and 2019

***Gross Revenue.*** We generated $147,000 gross revenue for the nine-month period ended September 30, 2020, in comparison with $169,900 for the comparable period a year ago. The decrease of $22,900 or 38% reflects the effects of the COVID-19 pandemic which caused the effective cessation of elective procedures in the United States from March through June, 2020.

***Cost of Goods Sold***. We generated $42,596 cost of goods sold for the nine-month period ended September 30, 2020, in comparison with $41,439 for the comparable period a year ago. The increase of $1,157 or 3% is due to the effect of the COVID-19 pandemic and slightly lower gross margins as incentives such as additional complementary kits were offered to new physician providers.

***Gross Profit/(Loss)***. We generated $104,404 in gross profit for the nine-month period ended September 30, 2020, in comparison with $128,461 for the comparable period a year ago. The decrease of $24,057 or 43% is due to the lower revenues and reduced margins referenced above.

***General and Administrative Expenses.*** General and administrative expenses for the nine-month period ended September 30, 2020, totaled $846,154, in comparison with $912,182, for the comparable period a year ago. The decrease of $66,028, or 19% is primarily due to a decrease of $66,591 in marketing expenses.

***Research and Development Expenses.*** There were no research and development expenses for the nine-month period ended September 30, 2020, and for the comparable period a year ago.

***Other Income / Expense.*** Other income for the nine-month period ended September 30, 2020, totaled $3,086,539 in comparison with other expense of $2,492,144, for the comparable quarter a year ago. The increase of $5,578,683, or 224% is primarily due to an increase in the gain in the fair value of derivative liabilities of $3,996,775, a $346,395 loss on extinguishment of convertible notes in 2019 and a $577,748 reduction in interest expense.

Net Loss. For the reasons stated above, our net income for the nine-month period ended September 30, 2020, totaled $2,294,768 in comparison to a loss of $3,291,723, for the comparable period a year ago.

### Liquidity and Capital Resources

Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem ED and FemCelz vaginal rejuvenation procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments.

For the next 12 months our plan of operations is to market our disposable kits and partner with leading researchers on investigator-initiated trials to advance our neurological programs. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

16

#### Table of Contents

### Cash Flows

***Net Cash used in Operating Activities.*** We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $491,542 for the nine-month period ended September 30, 2020 in comparison to $960,661 for the comparable period a year ago, a decrease of $469,119 or 49%. The decrease in cash used in operations was primarily related to a $276,200 increase in accounts payable and monies owed to CMH and a $31,705 increase in accounts payable and a $20,500 decrease in accounts receivable.

***Net Cash used in Investing Activities.*** There was no cash used in investing activities in the nine-month periods ended September 30, 2020 and September 30, 2019, respectively.

***Net Cash From Financing Activities.*** In the nine-month period ended September 30, 2020, we raised $458,600 through the issuance of convertible debt, retired $17,000 of convertible debt and did not pay any prepayment premiums on retired convertible notes. In the nine-month period ended September 30, 2019, we raised $1,047,295 through the issuance of convertible debt, expended $194,111 to retire convertible debt, and paid $38,343 in prepayment premiums on the retired convertible notes. The $373,241 or 46% decrease in cash flows from financing activities were primarily related to reduced levels of financing and lower loan repayments.

### Basis of Presentation / Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2020, the Company had $39,000 of available cash and a working capital deficit of $3,162,874. For the nine-month period ended September 30, 2020, the Company had $147,000 in revenue, $791,771 in operating loss and used net cash for operating activities of $491,542. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

17

#### Table of Contents

## Controls and procedures

As filed, 1,632 characters.

### Evaluation of disclosure controls and procedures

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2020.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

### Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

18

#### Table of Contents

Filed Nov 13, 2020.
Source: SEC EDGAR, the filing index for accession 0001477932-20-006527. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
